Relypsa Lands $10,000,000 Series A Financing Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=099580a5-e4c1-4b2a-b007-3b37c82555d9&Preview=1
Date 3/11/2009
Company Name Relypsa
Mailing Address 5301 Patrick Henry Drive Santa Clara, CA 95054
Company Description Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.